https://www.selleckchem.com/products/sr-18292.html
We found that rosiglitazone has different binding affinities for the same binding pockets of PPARγ and PPFP, and the optimal compound for PPFP can differ from that of PPARγ. This suggests the need for the development of drugs targeting PPFP that allow for the fusion, rather than focusing on the PPARγ side of PPFP and searching for the best compounds for that pocket. Our findings are expected to lead to the development of new therapies for thyroid tumors. Two pharmacokinetic/pharmacodynamic studies were conducted to evaluate the potenti
Like
Comment
Share
